Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement

Dow Jones

02/19

By Josh Beckerman

Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.

The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.

Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.

Faeth is developing drugs that target tumor metabolism and signaling.

On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. "We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies," the company said at the time.

Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 18, 2026 13:51 ET (18:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612423560"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612423560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612423560?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612423560","market":"sg","top_or_hot":-1,"title":"Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Shares Surge on Acquisition, Private Placement\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-19 02:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNSE","symbol_name":"Sensei Biotherapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612423560","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612423560","pubTimestamp":1771440660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.Faeth is developing drugs that target tumor metabolism and signaling.On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time.Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Sensei Biotherapeutics股价因收购和私募而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nSensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement. \n\n\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n\n\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n\n\n  Faeth is developing drugs that target tumor metabolism and signaling. \n\n\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n\n\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 13:51 ET (18:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}